Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

He added that the US market relies heavily on generic drugs rather than branded products, which Novo Nordisk does not sell. Competitor Eli Lilly (LLY) recently announced a $27 billion investment in ...

CHICAGO — Coby White scored 24 points, including a clutch four-point play, and the Bulls rallied to beat the Toronto Raptors 125-115 in overtime. White completed his biggest play of the night ...

Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...

Novo Resources Corp is poised to begin selecting drill targets at the John Bull and Tibooburra gold projects in New South Wales, having collected hundreds of soil and rock chip samples from both ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 billion ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If you’re on the fence about investing in Intra-Cellular Therapies, Inc. or Novo Nordisk A/S because you’re not sure how they measure up, it’s important to compare them on a few factors before making ...

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS).